Home/Filings/4/0001628280-23-036463
4//SEC Filing

Taveras Arthur 4

Accession 0001628280-23-036463

CIK 0001501697other

Filed

Nov 1, 8:00 PM ET

Accepted

Nov 2, 4:59 PM ET

Size

5.0 KB

Accession

0001628280-23-036463

Insider Transaction Report

Form 4
Period: 2023-10-31
Taveras Arthur
Chief Scientific Officer
Transactions
  • Award

    Common Stock

    2023-10-31+230,645317,018 total
Footnotes (1)
  • [F1]Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor.

Issuer

X4 Pharmaceuticals, Inc

CIK 0001501697

Entity typeother

Related Parties

1
  • filerCIK 0001830901

Filing Metadata

Form type
4
Filed
Nov 1, 8:00 PM ET
Accepted
Nov 2, 4:59 PM ET
Size
5.0 KB